Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1937

Sort by

Sort Order Select

Journal Articles

Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia

Jenny Klintman, Niamh Appleby, Basile Stamatopoulos, Katie Ridout, Toby A. Eyre, Pauline Robbe, Laura Lopez Pascua, Samantha J. L. Knight, Helene Dreau, Maite Cabes, Niko Popitsch, Mats Ehinger, Jose I. Martín-Subero, Elías Campo, Robert Månsson, Davide Rossi, Jenny C. Taylor, Dimitrios V. Vavoulis, Anna Schuh

Blood (2021) 137 (20): 2800–2816.

https://doi.org/10.1182/blood.2020005650

Published: 2021

Includes: Supplemental data

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA

Blood (2021) 137 (17): 2307–2320.

https://doi.org/10.1182/blood.2020008750

Published: 2021

Includes: Supplemental data

Journal Articles

Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy

Vindi Jurinovic, PhD, Verena Passerini, PhD, Mikkel Z Oestergaard, PhD, Andrea Knapp, PhD, Kirsten Mundt, PhD, Shamzah Araf, MRCP, MBBS, PhD, Julia Richter, PhD, Jude Fitzgibbon, PhD, Wolfram Klapper, Robert E. Marcus, FRCP, Andrew Davies, MD PhD, Michael Herold, MD, Wolfgang Hiddemann, PhD, Michael Unterhalt, PhD, Eva Hoster, PhD, Oliver Weigert, MD

Blood (2019) 134 (Supplement_1): 122.

https://doi.org/10.1182/blood-2019-130208

Published: 2019

Journal Articles

Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labled Study with Ddgp Regimen Versus SMILE Regimen

Blood (2019) 134 (Supplement_1): 463.

https://doi.org/10.1182/blood-2019-127811

Published: 2019

Journal Articles

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

Blood (2019) 134 (Supplement_1): 464.

https://doi.org/10.1182/blood-2019-122781

Published: 2019

Journal Articles

Analysis of an Online Treatment Decision Tool Reveals Variances in Practice between Experts and Oncology Healthcare Providers for Newly Diagnosed Follicular Lymphoma

Rachael M Andrie, John M Burke, MD, Christopher R. Flowers, MD MS, Nathan H Fowler, MD, Jeff P. Sharman, MD, Timothy A Quill, PhD, Kevin L Obholz, PhD, Ian W. Flinn, MD PhD

Blood (2019) 134 (Supplement_1): 414.

https://doi.org/10.1182/blood-2019-128988

Published: 2019

Journal Articles

Gene Polymorphisms and Vincristine-Induced Neuropathy in Patients Who Received R-CHOP Chemotherapy

Akihiko Sawaki, MD, Kana Miyazaki, MD PhD, Toshifumi Takeuchi, MD PhD, Kyoko Kobayashi, MD PhD, Hiroshi Imai, MD PhD, Isao Tawara, MD PhD, Ryoichi Ono, MD PhD, Tetsuya Nosaka, MD PhD, Motoko Yamaguchi, MD PhD, Naoyuki Katayama, MD PhD

Blood (2019) 134 (Supplement_1): 1624.

https://doi.org/10.1182/blood-2019-122796

Published: 2019

Journal Articles

Exploring the Potential of Shallow Whole-Genome Sequencing for Diagnosis and Disease Monitoring of Lymphoma in Liquid Biopsy

Lennart Raman, MSc, Malaïka Van Der Linden, MSc, Ciel De Vriendt, Bliede Van Den Broeck, MD, Kristoff Muylle, MD, Dries Deeren, MD PhD, Bjorn Menten, PhD, Fritz Offner, MD, Jo Van Dorpe, MD PhD

Blood (2019) 134 (Supplement_1): 2087.

https://doi.org/10.1182/blood-2019-131391

Published: 2019

Journal Articles

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Michael D. Jain, MD PhD, Anca Prica, MD, Ryan D. Morin, PhD, Vishal Kukreti, MD, Robert Kridel, MDMPH,PhD, Rob C. Laister, PhD, Li Meng, Christopher Rushton, Miguel Alcaide, Rashmi S. Goswami, MD PhD, Jan Delabie, MD PhD, Jessica Weiss, Tony Panzarella, M.Sc., P.Stat, Michael Crump, MD, David W. Scott, MBChB, PhD, John Kuruvilla, MD

Blood (2019) 134 (Supplement_1): 2027.

https://doi.org/10.1182/blood-2019-131818

Published: 2019

Journal Articles

What Links Neutropenia to Immature Cardiolipin in Patients with Barth Syndrome (tafazzin-deficiency)?

Jihee Sohn, PhD, Thomas Brouse, Najihah Aziz, David B Sykes, MD PhD

Blood (2019) 134 (Supplement_1): 3579.

https://doi.org/10.1182/blood-2019-123680

Published: 2019

Journal Articles

Real-World Treatment Patterns and Overall Survival Among Medicare Fee-for-Service Beneficiaries Newly Diagnosed with Peripheral T-Cell Lymphoma

Anne Shah, MS, Allison Petrilla, MPH, Mayvis Rebeira, PhD, Joseph Feliciano, PharmD, Thomas W. LeBlanc, MDMA,MHS, Julie Lisano, PharmD

Blood (2019) 134 (Supplement_1): 3492.

https://doi.org/10.1182/blood-2019-130973

Published: 2019

Journal Articles

Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R 2 -CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQoL) Analysis of the International Robust Study

Blood (2019) 134 (Supplement_1): 3475.

https://doi.org/10.1182/blood-2019-123948

Published: 2019

Journal Articles

Disparities in Barriers and Facilitators of Acute Leukemia Diagnosis in Young Patients

Lucky Ding, BA, Ashley E Martin, MPH, Emma Canepa, MS, Erica Evans, MD, Richard Aplenc, MD PhD, Julia E Szymczak, PhD, Galen Joseph, PhD, Lena E. Winestone, MD MSHP

Blood (2019) 134 (Supplement_1): 3415.

https://doi.org/10.1182/blood-2019-124236

Published: 2019

Journal Articles

Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphoma Patients Receiving First-Line Treatment in Routine Clinical Practice in France and the United Kingdom

Christopher P Fox, MBChB(Hons), MRCP, FRCPath, PhD, Ajibade O Ashaye, MD MBA, MPH, MSc., Ruchit Shah, PhD, Shelby Corman, PharmD, MS, BCPS, Mehul Dalal, PhD, Lorenz Truemper, MD

Blood (2019) 134 (Supplement_1): 3482.

https://doi.org/10.1182/blood-2019-127289

Published: 2019

Journal Articles

Novel Drugs and Clinical Trial-Based Treatments Prolong Survival of Peripheral T-Cell Lymphomas (PTCL) Patients: Single Institution Retrospective Analysis

Helen Ma, MD, Enrica Marchi, MD, PhD, Bin Cheng, PhD, Govind Bhagat, MD, Owen A. O'Connor, MD PhD

Blood (2019) 134 (Supplement_1): 3486.

https://doi.org/10.1182/blood-2019-123587

Published: 2019

Journal Articles

CEOP/IVE/GDP Alternating Regimen Compared with CEOP As the First-Line Therapy for Newly Diagnosed Patients with Peripheral T-Cell Lymphoma: Results from a Phase 2, Multi-Center, Randomized, Controlled Clinical Trial

Mingci Cai, MD, Shu Cheng, MD PhD, Wang Xin, PhD, Jianda Hu, PhD, Yongping Song, Zixun Yan, Yujie Jiang, MD, Xiaosheng Fang, PhD, Xiaoyun Zheng, Lihua Dong, Mengmeng Ji, Li Wang, MD PhD, Pengpeng Xu, Weili Zhao

Blood (2019) 134 (Supplement_1): 1556.

https://doi.org/10.1182/blood-2019-122369

Published: 2019

Journal Articles

A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes

Juan Carlos Ramos, MD BS, Joseph Sparano, MD, Page C. Moore, PhD, Eric Siegel, Jeannette Y Lee, PhD, Erin G. Reid, MD MS, Richard F. Ambinder, MD, Amy Chadburn, MD, Paul G. Rubinstein, MD, Christine Durand, Ethel Cesarman, MD PhD, Lee Ratner, MD PhD, Robert A Baiocchi, MD PhD, David M. Aboulafia, MD, Lawrence D Kaplan, MD, Adam Capoferri, Ronald T. Mitsuyasu, MD, Ariela Noy, MD

Blood (2019) 134 (Supplement_1): 1588.

https://doi.org/10.1182/blood-2019-129687

Published: 2019

Journal Articles

Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results

Jason R. Westin, MD, Loretta J. Nastoupil, MD MSc, Luis Fayad, MD, Fredrick B. Hagemeister, MD, Yasuhiro Oki, MD, Francesco Turturro, MD, Sairah Ahmed, MD, Maria Alma Rodriguez, MD, Hun Ju Lee, Raphael Eric Steiner, MD, Ranjit Nair, MBBS,MD, Simrit Parmar, MBBS, Ken H. Young, Timothy J. McDonnell, MD PhD, Hubert Chuang, Michael R Green, PhD, Sattva S Neelapu, MD, Eric Davis, MD

Blood (2019) 134 (Supplement_1): 1581.

https://doi.org/10.1182/blood-2019-128475

Published: 2019

Journal Articles

Pipeline for Discovering Neoepitopes Generated By Alternative Splicing in B-ALL

Sisi Zheng, MD, Ammar S. Naqvi, PhD, Elisabeth Bolton-Gillespie, Mukta Asnani, Katharina Hayer, Yoseph Barash, PhD, Andrei Thomas-Tikhonenko, PhD

Blood (2019) 134 (Supplement_1): 1342.

https://doi.org/10.1182/blood-2019-131277

Published: 2019

NARROW

Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA

Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy

Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labled Study with Ddgp Regimen Versus SMILE Regimen

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

Analysis of an Online Treatment Decision Tool Reveals Variances in Practice between Experts and Oncology Healthcare Providers for Newly Diagnosed Follicular Lymphoma

Gene Polymorphisms and Vincristine-Induced Neuropathy in Patients Who Received R-CHOP Chemotherapy

Exploring the Potential of Shallow Whole-Genome Sequencing for Diagnosis and Disease Monitoring of Lymphoma in Liquid Biopsy

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

What Links Neutropenia to Immature Cardiolipin in Patients with Barth Syndrome (tafazzin-deficiency)?

Real-World Treatment Patterns and Overall Survival Among Medicare Fee-for-Service Beneficiaries Newly Diagnosed with Peripheral T-Cell Lymphoma

Disparities in Barriers and Facilitators of Acute Leukemia Diagnosis in Young Patients

Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphoma Patients Receiving First-Line Treatment in Routine Clinical Practice in France and the United Kingdom

Novel Drugs and Clinical Trial-Based Treatments Prolong Survival of Peripheral T-Cell Lymphomas (PTCL) Patients: Single Institution Retrospective Analysis

CEOP/IVE/GDP Alternating Regimen Compared with CEOP As the First-Line Therapy for Newly Diagnosed Patients with Peripheral T-Cell Lymphoma: Results from a Phase 2, Multi-Center, Randomized, Controlled Clinical Trial

A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes

Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results

Pipeline for Discovering Neoepitopes Generated By Alternative Splicing in B-ALL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only